Latest News
Almirall reports lebrikizumab demonstrated sustained long-term control in atopic dermatitis through four years
27 March 2026 - Spanish pharmaceutical company Almirall S.A. (BME:ALM) on Friday reported positive long-term interim results from the Phase 3b ADlong study evaluating lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis.Da...
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
27 March 2026 - Biotechnology company Rocket Pharmaceuticals Inc (NASDAQ:RCKT) announced on Friday that the US Food and Drug Administration (FDA) has granted accelerated approval for Kresladi (marnetegragene autotemcel) for paediatric patients with s...
AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials
27 March 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) reported on Friday that tozorakimab met the primary endpoint in both the OBERON and TITANIA Phase III trials evaluating patients with chronic obstructive pulmona...
Pharming receives positive CHMP opinion for Joenja marketing authorisation
...
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
27 March 2026 - Biotechnology company Biocytogen Pharmaceuticals (Beijing) Co Ltd (SSE:688796) (HKEX:02315) announced on Friday that its partner NEOK Bio Inc has received US Food and Drug Administration (FDA) clearance for an investigational new drug...